Pfizer (PFE) closed at $29.39 on November 6, 2026, down 0.2% from the previous close, on volume of 36,124,416 shares (30-day average 32,775,418).
Data as of November 6, 2026.
Democratic lawmakers seen probing Trump drug pricing deals come January
Seeking Alpha News (Fri, 6-Nov 12:13 PM ET)
Pfizer Advances Monthly Sleep Apnea Drug Study as Investors Watch Its Pipeline
TipRanks (Fri, 6-Nov 11:32 AM ET)
Pfizer Advances Monthly Obesity Drug Study in China
TipRanks (Fri, 6-Nov 11:32 AM ET)
Pfizer Advances Early Berobenatide Delivery Study in Obesity Drug Race
TipRanks (Fri, 6-Nov 11:32 AM ET)
Pfizer Advances Phase 3 RSV Vaccine Study in High-Risk Children
TipRanks (Fri, 6-Nov 11:30 AM ET)
Pfizer Updates Ulcerative Colitis Treatment-Pattern Study: What Investors Should Know
TipRanks (Fri, 6-Nov 11:30 AM ET)
TipRanks (Thu, 5-Nov 4:50 PM ET)
Half of RFK Jr. health panel appointees granted waivers to keep stocks: NY Times
Seeking Alpha News (Thu, 5-Nov 4:49 PM ET)
Pfizer Advances Monthly Obesity Drug Study as Investors Watch for a Competitive Edge
TipRanks (Thu, 5-Nov 11:32 AM ET)
Pfizer (PFE) Stock Looks Attractive for Income Investors
TipRanks (Thu, 5-Nov 8:32 AM ET)
Pfizer is one of the world's largest pharmaceutical firms, with annual sales of roughly $60 billion. While it historically sold many types of healthcare products and chemicals, now prescription drugs and vaccines account for the majority of sales. Top sellers include pneumococcal vaccine Prevnar 13 and cardiology drugs Vyndamax and Eliquis. Pfizer sells these products globally, with international sales representing 40% of total sales. Within international sales, emerging markets are a major contributor.
Pfizer trades on the NYSE stock market under the symbol PFE.
As of November 6, 2026, PFE stock price declined to $29.39 with 36,124,416 million shares trading.
PFE has a beta of 0.19, meaning it tends to be less sensitive to market movements. PFE has a correlation of 0.02 to the broad based SPY ETF.
PFE has a market cap of $167.09 billion. This is considered a Large Cap stock.
Last quarter Pfizer reported $17 billion in Revenue and $.87 earnings per share. This beat revenue expectation by $656 million and exceeded earnings estimates by $.14.
In the last 3 years, PFE traded as high as $31.54 and as low as $20.92.
The top ETF exchange traded funds that PFE belongs to (by Net Assets): VTI, VOO, IVV, SPY, VTV.
PFE has outperformed the market in the last year with a price return of +26.4% while the SPY ETF gained +9.6%. PFE has also outperformed the stock market ETF in the last 3 month and 2 week periods returning +13.9% and -3.4%, respectively, while the SPY returned -4.2% and -3.8%, respectively.
PFE support price is $29.02 and resistance is $29.88 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that PFE shares will trade within this expected range on the day.